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Abstract
Vegetables contain unknown compounds with health promoting effect, since 
the effects of the known nutrients and other bioactive compounds, such as vitamins, 
minerals, fatty acids and fibres, cannot explain the benefits of high intake of 
vegetables. Most biologically active substances have never been investigated for 
health-promoting properties, often because they have historically been considered 
health hazards, due to toxicity at high levels of intake. However, to improve the value 
of vegetables for health, it is necessary to identify which compounds are most 
important, and find ways to manage “paradoxical” effects where the same compound 
is good or bad for health depending on dose. However, there are thousands of chemical 
constituents in plants, and it would be very expensive and time consuming to test each 
of them thoroughly. The described project defined and tested a two-step screening 
procedure for identification of compounds with impact on human health, to reduce 
the number and make this difficult task manageable. 
Step 1 is initial screening according to three criteria: 1.1, chemically reactive 
functional groups; 1.2, toxicity at high concentrations or other bioactivity; and 
1.3, presence in healthy foods. 
Step 2 is testing for minimum criteria defining health-promoting compounds: 
2.1, positive or biphasic (“hormesis”) responses in bioassay; 2.2, human tissue concen-
trations corresponding to beneficial effects in bioassay; and 2.3, possibility to control 
content in food. 
Compounds that pass both screens should be subjected to more extensive (and 
expensive) investigations in vivo and in vitro (Step 3). 
The natural pesticide and toxicant falcarinol from carrots fulfilled all 6 criteria 
and subsequently showed anticancer effect in rats. Several other bioactive compounds 
in vegetables, mostly classified as toxicants, also have properties that indicate disease-
preventing properties, for example glucosinolates in cabbage and its relatives, 
sesquiterpene lactones in lettuce and glycoalkaloids in potatoes. 
INTRODUCTION
The health benefits of a high intake of vegetables has been known for a long time: 
the preventive effect on cancer was recognised more than a century ago (Williams, 1898), 
and many subsequent epidemiological studies have confirmed negative correlations 
between the intake of vegetables and fruits and the incidence of important diseases such 
as cancer and atherosclerosis, as reviewed by Trichopoulou et al. (2003), Kris-Etherton et 
al. (2002) and Maynard et al. (2003). 
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Williams (1898) strongly advocated appropriate lifestyle changes (where he 
focused on decreased intake of meat, increased consumption of fresh vegetables and more 
physical exercise) as the primary target for society’s efforts to limit the increase in cancer. 
While his message is now universally understood and accepted, actual implementation 
has turned out to be exceedingly difficult. However, if we could identify the specific 
health-promoting compounds in the vegetables, it would in theory be possible to obtain 
similar benefits by increasing the intake of these compounds by other means. This could 
be achieved by either increasing the levels present in the (relatively low amount of) 
vegetables that are consumed, or by using the health-promoting compounds as food 
supplements.
Health Promoting Compounds in Vegetables and Fruits in General 
Vegetables and fruits are known to contain components with several types of 
health promoting actions (as vitamins, as essential minerals, as antioxidants and as pre-
biotics (fibres)). The data from epidemiological studies shows sufficient linearity across 
the range to allow calculations of the benefits of substantial increases in the intake of 
fruits and vegetables to 400 g per day (van’t Veer et al., 2000) or even higher (Gundgaard 
et al., 2003), with the conclusion that more than 400 g per day gives a significantly longer 
predicted life expectancy than the present average intake in Europe of around 260 g per 
day (Agudo et al., 2002). This should be compared with the lower levels (approx. 200 g 
per day) needed to ensure against deficiencies of all the known beneficial compounds for 
which vegetables are the primary dietary sources (Ali and Tsou, 2002). In addition, a few 
compounds are known or suspected to benefit health by other, less understood 
mechanisms, such as protection against cardiovascular disease by sulfoxides and/or 
flavonoids from Alliums (Griffiths et al., 2002) or anticancer effects of glucosinolates 
from Brassicas and their derivatives (Thomalley, 2002). However, the epidemiological 
correlations are not confined to these two types of vegetables, so if non-nutrient 
phytochemicals are responsible for the health benefits of vegetables, there should be 
compounds with similar effects present in many other foods as well. 
Carotenes as Potentially Disease Preventing Compounds in Carrots 
For carrots, the existing knowledge is particularly confusing. Carrots are the 
primary dietary sources of ?-carotene in most countries in Europe and in the USA 
(O'Neill et al., 2001), and provide more than 60% of the intake of ?-carotene. ?-carotene
is the most abundant provitamin A carotenoid in the diet and accounts for a significant 
part of human provitamin A intake. Vitamin A deficiency is a significant public health 
problem in many developing countries. Severe deficiency causes night blindness and can 
lead to complete blindness, while less severe deficiencies affect at least 250 million 
preschool-age children worldwide by causing increased susceptibility to various 
infectious diseases, including diarrhoea, measles and respiratory infections. 
Supplementation with vitamin A has been shown to reduce childhood mortality by 40% 
and maternal mortality by 44% (Sommer and West, 1996; West et al., 1999). 
Studies in affluent populations with fully adequate vitamin A status consistently 
show reduced risk of cancer and cardiovascular disease in people with a higher than 
average intake of ?-carotene-containing vegetables, measured either as reported intake or 
through measurement of the ?-carotene-content in plasma (Fig. 1a) (Stanner et al., 2003; 
Greenberg et al., 1996; Albanes et al., 1996; Omenn et al., 1996). However, until now no 
studies of controlled supplementation with ?-carotene in well-nourished populations have 
shown unequivocal benefits (Stanner et al., 2003; Greenberg et al., 1996), and the two 
studies with the largest number of cancer cases (obtained by preferential enrolment of 
smokers) found that it significantly increased the risk of cancer (Fig. 1b) (Albanes et al., 
1996; Omenn et al., 1996). When comparing Figs. 1a and 1b, it must be emphasised that 
the data in each figure represents the same persons, and that neither study showed any 
interaction between the positive effects of a high baseline level of ?-carotene and the 
negative effect of supplementation. This means that these opposing trends are not due to 
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atypical effects of ?-carotene in smokers (since the smokers with a ?-carotene-rich diet 
benefited as much as other populations), nor does it support the notion of some 
mysterious interaction between ?-carotene and other food components (since people with 
a high baseline ?-carotene content did not benefit from boosting with additional ?-
carotene, even though their diet must have comprised the synergist). 
Another puzzling observation about carotenes, cancer and carrots is that in four 
out of five studies where intake or plasma levels of both ?-carotene and ?-carotene have 
been compared with lung cancer incidence, has the negative correlation with ?-carotene
been stronger than for ?-carotene (Wright et al., 2003; Ito et al., 2005; Michaud et al., 
2000; Knekt et al., 1999; Ziegler et al., 1996), even though the efficiency of conversion of 
?-carotene into vitamin A is only about half of that for ?-carotene (Standing Committee 
on the Scientific Evaluation of Dietary Reference, 2001). 
The simplest unifying explanation for all of these observations is that carrots 
contain at least one compound with substantial cancer-preventive effect, which is not a 
carotene. This then implies that some or all of the negative correlations of disease 
incidence in populations not deficient in vitamin A with ?-carotene and ?-carotene intake 
would be due to the carotenes acting as markers for carrot intake, with ?-carotene being a 
more precise measure than ?-carotene.
Need for a Strategy for Screening 
The objective of the present study was to define a systematic screening strategy, 
which as efficiently as possible would allow us to distinguish plant components where a 
modest (few-fold) increase of the normal dietary levels is likely to cause a substantial 
improvement in human health, from compounds where this is less likely (Brandt et al., 
2004).
MATERIALS AND METHODS 
Development of Screening Method 
Based on the concepts used for identifying pharmaceuticals (Garrett and 
Workman, 1999) and the type of information required to make health claims for food 
(Aggett et al., 2005), a procedure was designed to discriminate among compounds in 
vegetables that are more or less likely to have important health-promoting impact. Two 
simple “minimum requirements” were formulated so they can be estimated by combining 
existing literature data with data that can be obtained from relatively simple studies of cell 
cultures and human bioavailability. They are: 
Minimum Requirement 1: A physiological effect on human tissue must be likely. 
It can be estimated by the formula: Physiological effect = concentration in food * 
intake of food * bioavailability of compound * bioactivity (= effect on cells) of compound 
at the physiological concentration. 
Minimum Requirement 2: The physiological effect on human tissue should be 
non-toxic.
Estimated by: The concentration in vivo should be in a range where in vitro 
studies indicate that positive physiological effects are more likely than toxic effects. 
Testing of Screening Method 
The method was tested on compounds representing 7 different chemical groups. 
Excluding those compounds which were already well known as health-promoting, the 
highest ranking compound was tested for anti-cancer effect in an animal model using 
azoxymethane (AOM) induced colon preneoplastic lesions in male BDIX rats (Kobæk-
Larsen et al., 2002). Three groups of each 8 AOM treated rats were fed the standard rat 
feed Altromin® supplemented with either 10% (w/w) freeze dried carrots with a natural 
content of the compound, 10% maize starch to which the compound purified from carrots 
was added to obtain the same concentration as in the carrots, or 10% maize starch 
(control). After eighteen weeks the colon was examined for tumours and aberrant crypt 
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foci (ACF), which were classified into 4 size classes: “Small”, 1–3 crypts; “Medium”, 
4-6 crypts; “Large”, ?7 crypts, (diameter ?1 mm) and “Tumors” (diameter ?1 mm). 
RESULTS AND DISCUSSION 
The developed screening procedure: 
A three step procedure was formulated: 1. Initial screening/ranking using data 
generally available in the literature, 2. Assessment of key properties, which often requires 
(relatively low cost) experiments. 3. Confirmation of effect in vivo. After each step 
unsuccessful candidate compounds are eliminated, and the successful ones ranked 
according to how well the criteria are fulfilled. 
The criteria used for selection and ranking of candidates in step 1 were defined as; 
1.1. Presence of chemically reactive functional groups or other chemical properties 
indicating likely interaction with cell components. 
1.2. Known effect on some physiological functions in humans, such as the immune 
system (allergenic) or the kidneys (diuretic), toxicity at high concentrations or 
other known bioactivity including antimicrobial and antinutritional effects. 
1.3. Presence in foods which are widely consumed, preferably foods epidemiologically 
linked with decreased risk of disease, indicating absence of direct toxicity at the 
concentrations normally found in food and indicating good prospects that new 
knowledge can and will be utilised to improve diets. 
The criteria used for testing in step 2 were defined as: 
2.1. Dose-dependent biological response in one or more relevant bioassays, which 
indicates some positive effect on health (not necessarily specific for a particular 
mode of action), and which also allows recording of toxic effects at super-optimal 
concentrations.
2.2. That after ingestion of a relevant food, concentration in a human tissue reaches 
levels corresponding to the range that elicits the potentially positive effects shown 
in the bioassay of criterion 2.1. This would indicate that the bioavailability is 
sufficiently high to ensure that the effects tested in the bioassay are physio-
logically relevant, but not so high that toxic effects are likely to predominate. 
2.3. A variable occurrence in food raw materials (e.g. a response to common 
processing methods and/or significant differences among plant cultivars), which 
show that the content in foods can be controlled and optimised using existing or 
only slightly adapted technology. 
The principles for confirmation in step 3 were defined as: 
3.1 Using a full in vivo model relevant for the expected type of effect, with definitive 
endpoints.
3.2 Comparison of the plant food where the compound normally occurs, with the 
isolated compound in the same amount as in the food, and a relevant control. 
Outcome of Screening 
For the initial screening (step 1), the following compounds did best (starting with 
the highest rank): 1. Glucosinolates, 2. Onion sulphur compounds, 3. Polyacetylenes 
including falcarinol, 4. Glycoalkaloids, 5. Sesquiterpene lactones, 6. Coumarins and 
7. Antioxidant phenolic and carotenoids (Brandt et al., 2004). 
1, 2 and 7 are already under extensive investigation for health promoting effects, 
so 3 was chosen for assessments of the step 2 criteria, and 4, 5 and 6 recommended for 
investigation in other projects. Note that the relevant experiments for step 2 assessments 
of 7 (antioxidants) have already been carried out and reported in the literature, and in 
most cases (if not all) the result for 2.2 is negative: the tissue concentrations in vivo are 
too low to display the antioxidant effects seen in vitro. The screening procedure thus 
classifies the antioxidants as relatively unlikely to benefit health, unless more convincing 
data are obtained in well-designed experiments. 
The step 2 assessments showed that the carrot constituent falcarinol (Fig. 2), 
which was previously described as a food toxicant (Gry et al., 1998), has dose-dependent 
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effect on the proliferation of primary mammary epithelial cells from pre-pubertal heifers 
(Hansen et al., 2003), fulfilling criterion 2.1, with stimulatory effects in the range 1–
50 ng ml-1 (and no effect of ?-carotene at any concentration), that ingestion of a few 
glasses of carrot juice results in a plasma concentration of 1–2 ng ml-1 (Haraldsdottir et 
al., 2002) fulfilling criterion 2.2, and that the content is affected by processing (Hansen et 
al., 2003) and differs among cultivars (Kidmose et al., 2004), fulfilling criterion 2.3, so a 
step 3 confirmation was decided. 
The best documented important health impact of carrot consumption is prevention 
of cancer, so for the in vivo model was chosen one that mimics human colon cancer and is 
suitable for dietary modulation (Kobæk-Larsen et al., 2002). 
As shown in Fig. 2, although the number of small ACF was unaffected by the 
feeding treatments, the numbers of lesions as function of increasing size class decreased 
significantly in the rats that received one of the two experimental treatments, as compared 
with the control treatment (Kobæk-Larsen et al., 2005). This indicates that the dietary 
treatments with carrot and falcarinol delayed or retarded the development of large ACF 
and tumours. This study thus shows to what extent falcarinol could be responsible for 
cancer prevention in rats, although the effect is not directly applicable to humans. 
However, a similar study conducted in ferrets, which metabolise ?-carotene at a similar 
rate as humans (Lederman et al., 1997), or in a rodent model where the activity of the ?-
carotene monoxygenase (BCMO1) enzyme is down-regulated to simulate human enzyme 
activity levels, would allow to obtain a more definitive conclusion on the relevance and 
relative importance of both falcarinol and ?-carotene for the anti-cancer effect of carrots. 
CONCLUSIONS
The study shows that a systematic approach using the concepts of modern drug 
discovery can be very effective for identifying the compounds most likely responsible for 
health-promoting effects of vegetables. It also provides a new perspective on the known 
epidemiological associations between high intake of carrots and reduced incidence of 
cancers, implying that a natural pesticide of carrots, falcarinol, appears to be responsible 
for some or most of this effect, at the low concentrations found in food, rather than the 
antioxidant ?-carotene, which has earlier been in focus in this context. 
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Figurese
Fig. 1. Incidence of lung cancer in two large studies, “ATBC” with a study population of 
29133 (Albanen et al., 1996) and “CARET” with 18314 (Omenn et al., 1996). 1a: 
Incidence as a function of the plasma concentration of ?-carotene at baseline 
compared with the median value. 1b: Incidence as a function of supplementation 
with ?-carotene. Supplementation was given to a randomly selected half of the 
members of each study population at daily doses of 20 or 30 mg per day, 
respectively. 
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Fig. 2. The relative numbers of tumours and ACF in the colons of AOM-treated rats fed a 
diet supplemented with 10% maize starch (control), 10% freeze dried carrot with a 
natural content of 35 µg falcarinol/g or 10% maize starch supplemented with 
35 µg falcarinol/g. Bottom left shows the chemical structure of the polyacetylene 
falcarinol, a natural pesticide. 
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